Literature DB >> 31017658

Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.

Z N Willsmore1, R T Woolf1, C Hughes2, B Menon2, B Kirkham2, C H Smith1, A E Pink1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31017658     DOI： 10.1111/bjd.18031

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

Review 1.  Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies.

Authors:  Tobias Russell; Charlie Bridgewood; Hannah Rowe; Ala Altaie; Elena Jones; Dennis McGonagle
Journal:  Semin Immunopathol       Date:  2021-02-05       Impact factor: 11.759

Review 2.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

3.  Exacerbation of IgA nephropathy in a patient receiving dupilumab.

Authors:  Masako Yamamoto; Yuriko Kawase; Emi Nakajima; Yoshiaki Matsuura; Wataru Akita; Ryousuke Aoki; Yusuke Suzuki; Hiroshi Mitsui
Journal:  JAAD Case Rep       Date:  2022-01-19

4.  Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management.

Authors:  Ryan Jay; Jaimie Rodger; Matthew Zirwas
Journal:  JAAD Case Rep       Date:  2022-01-06

5.  Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis.

Authors:  Ecem Bostan; Duygu Gülseren; Zehra Özsoy; Fatma Bilge Ergen
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.007

6.  Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.

Authors:  Joaquim Mullol; Tanya M Laidlaw; Claus Bachert; Leda P Mannent; G Walter Canonica; Joseph K Han; Jorge F Maspero; Cesar Picado; Nadia Daizadeh; Benjamin Ortiz; Yongtao Li; Marcella Ruddy; Elizabeth Laws; Nikhil Amin
Journal:  Allergy       Date:  2021-10-01       Impact factor: 14.710
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.